ASP1570 + pembrolizumab + Trifluridine + Tipiracil + Bevacizumab + Docetaxel + Oxaliplatin + Leucovorin + 5-Fluorouracil + Irinotecan + Pemetrexed + Carboplatin
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumors
Conditions
Advanced Solid Tumors
Trial Timeline
Oct 19, 2021 → May 31, 2028
NCT ID
NCT05083481About ASP1570 + pembrolizumab + Trifluridine + Tipiracil + Bevacizumab + Docetaxel + Oxaliplatin + Leucovorin + 5-Fluorouracil + Irinotecan + Pemetrexed + Carboplatin
ASP1570 + pembrolizumab + Trifluridine + Tipiracil + Bevacizumab + Docetaxel + Oxaliplatin + Leucovorin + 5-Fluorouracil + Irinotecan + Pemetrexed + Carboplatin is a phase 1/2 stage product being developed by Astellas Pharma for Advanced Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05083481. Target conditions include Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05083481 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumors